The organs worked. The rejection came slowly enough to be measured.
In a hospital in Guangxi, China, a team of surgeons crossed a threshold that medicine had long approached but never breached: for the first time, two pig kidneys and a complete liver — all from a single genetically modified animal — were transplanted simultaneously into a human body. The patient, a brain-dead man whose family consented to the experiment, briefly hosted organs that functioned before his immune system began to resist them. This five-day procedure, published in the journal Med in May 2026, does not yet promise a cure for the global organ shortage, but it moves the boundary between the impossible and the merely unsolved.
- Thousands of patients die each year waiting for donor organs, and xenotransplantation has long been medicine's most audacious proposed answer — now, for the first time, a multi-organ version of that answer has been tested in a human body.
- Within 19 hours, the pig liver was producing bile and kidney markers had normalized, offering a brief, striking window of cross-species biological cooperation.
- After 36 hours, the immune system mobilized — tissue death appeared in the liver, clotting patterns shifted, and elevated S100A12+ inflammatory cells signaled the body's deep resistance to foreign tissue.
- The experiment ran five days before the family asked it to stop, leaving researchers with both a proof of concept and a precise map of where the science must go next.
- Crucially, no living patient was placed at risk — the controlled conditions of a brain-dead subject allowed the team to observe rejection safely, making the ethical framework as notable as the surgical achievement.
- Researchers are explicit: years of further study, refined genetic modifications, and better immunosuppressive strategies stand between this milestone and a transplant that could save a living person's life.
In a hospital in Guangxi, China, surgeons performed something that had never been done before: they placed two kidneys and a complete liver from a single genetically modified pig into one human body. The patient was a 53-year-old man declared brain-dead after a cerebral hemorrhage. With his family's authorization, his body was kept functioning artificially so the team from Guangxi Medical University could conduct this unprecedented xenotransplantation experiment.
The pig had been altered with six genetic modifications — three of its own genes removed, three human genes inserted — in an effort to reduce the body's impulse to reject foreign tissue. The early results were striking. Within 19 hours, the pig liver was producing bile. Kidney markers that had been abnormal due to the patient's chronic kidney disease returned to normal. For the first full day, there were no signs of rejection.
Then, at the 36-hour mark, the immune system began to fight back. Areas of tissue death appeared in the liver, and blood clotting patterns shifted. Researchers identified high concentrations of S100A12+ immune cells — drivers of inflammation and tissue damage — as a key mechanism of rejection. Yet despite these warning signs, the organs continued to function until the family requested the experiment be stopped on day five. The findings were published in the journal Med in May 2026.
What makes this case significant is the accumulation of firsts: the first complete pig liver ever transplanted into a human, the first simultaneous multi-organ xenotransplant, and the first detailed observation of how the human immune system responds to such a combination. Previous xenotransplants had involved single organs; this was entirely new territory.
The researchers are careful not to overstate what was achieved. This was an experiment on a deceased patient under controlled conditions — no living person was exposed to the risks of rejection. The goal was to gather data, and the data gathered is now the foundation for the next phase of work: refining genetic modifications, developing better immunosuppressive therapies, and finding ways to extend organ function from days toward weeks and months. The organ shortage that kills thousands each year remains unsolved, but the boundary between impossible and merely difficult has, in a Guangxi operating room, quietly moved.
In a hospital in Guangxi, China, surgeons performed an operation that had never been attempted before: they transplanted two kidneys and a complete liver from a genetically modified pig into a single human body. The patient was a 53-year-old man who had suffered a cerebral hemorrhage and been declared brain-dead. With his family's permission, doctors kept his body functioning artificially so they could conduct this unprecedented experiment in xenotransplantation—the transplant of animal organs into humans.
The pig had undergone six genetic modifications: three of its own genes were removed, and three human genes were inserted. The goal was straightforward but ambitious: reduce the body's natural impulse to reject foreign tissue. Within 19 hours of surgery, the pig liver was producing bile. The kidney markers that had been abnormal due to the patient's chronic kidney disease returned to normal levels. For the first day, there were no signs of rejection at all. The organs appeared to be working.
Then, after 36 hours, the immune system began to fight back. Areas of tissue death appeared in the liver. Blood clotting patterns shifted. Yet despite these warning signs, the organs continued to function. The experiment ran for five days total, until the family requested that it be stopped. The research team published their findings in the journal Med in May 2026.
What makes this case historically significant is not just that it happened, but what it reveals about the frontier of transplant medicine. Previous xenotransplants had involved single organs. No one had ever transplanted a complete pig liver into a human before. The combination of two kidneys and a liver from the same animal, in the same patient, was entirely new territory. The team from Guangxi Medical University had pushed past a boundary that had held for decades.
The early success matters because it proves the concept can work, at least briefly. The liver functioned. The kidneys functioned. The organs did what they were designed to do. But the rejection that followed matters just as much. The researchers found high concentrations of immune cells called S100A12+, which drive inflammation and tissue damage. Understanding why these cells mobilized, and how to prevent that mobilization, is now the central question.
The researchers are careful not to overstate what they have accomplished. This was an experiment on a deceased patient, not a living one. No living person was exposed to the risks of xenotransplant rejection. The procedure was designed to gather data under controlled conditions—to watch how human tissue responds to pig organs without putting a conscious patient in danger. That distinction matters enormously in medical ethics and in the realistic timeline for bringing this technology to patients who need it.
The shortage of human organs for transplant is a crisis that kills thousands of people every year. Xenotransplantation, if it can be made safe and reliable, could transform that reality. But the path from a five-day experiment on a brain-dead patient to routine transplants in living people is long. The researchers themselves acknowledge that many more studies will be needed. The genetic modifications helped, but they were not enough to prevent rejection entirely. Future work will likely focus on refining those modifications, developing better immunosuppressive therapies, or finding ways to educate the immune system to tolerate the foreign tissue rather than attack it.
For now, this case stands as a proof of concept—evidence that the boundary between impossible and merely difficult has shifted. The organs worked. The rejection came, but it came slowly enough that the team could observe it, measure it, and learn from it. That learning is the real product of this surgery. The next chapter will be written by researchers trying to extend that window of function from days to weeks, from weeks to months, from months to years. Whether they succeed will determine whether xenotransplantation becomes a routine part of medicine or remains a fascinating dead end.
Notable Quotes
The experiment showed that the combination of pig organs can function for at least a short period, but many more studies will be necessary before this can be applied to living patients— Guangxi Medical University research team
The Hearth Conversation Another angle on the story
Why use a brain-dead patient for this instead of waiting until the technology was safer for living people?
Because you can't know if it's safe without testing it somewhere. A living patient would face real danger. A brain-dead patient whose body is being maintained artificially allows the team to gather data without exposing anyone to new risk. The family consented knowing it was research, not treatment.
The liver produced bile within 19 hours. That sounds like success. Why does rejection matter if the organs kept working for five days?
Rejection is what kills transplants. Those first 36 hours without rejection signs were encouraging, but the immune cells that showed up later—they would have destroyed the organs eventually. Five days is just the beginning of that process. In a living patient, you'd need the organs to last years.
The pig had six genetic changes. Wasn't that enough?
It helped. Without those modifications, rejection probably would have happened much faster. But it wasn't enough to stop it entirely. The modifications bought time and showed which immune pathways are the problem. Now researchers know what to target next.
What happens to this data now?
Other teams will study it, try different genetic modifications, test new drugs to suppress rejection more effectively. Some will try combining pig organs with human cells. Others will work on ways to make the human immune system tolerate the foreign tissue rather than attack it. This one experiment opens a dozen new research directions.
Could this have been done on a living volunteer who understood the risks?
Legally and ethically, probably not yet. The rejection signs appeared within 36 hours. A living patient would have suffered organ failure, possibly death. You need to prove the concept works and understand the failure modes before you ask someone to take that risk. That's what this experiment did.